Gilead Set to Acquire Higher Stake in Galapagos for $5.1 Billion

Belgian biotech firm Galapagos has struck a new deal with Gilead Sciences where the latter will acquire a larger stake for $5.1 billion. The deal is the largest yet by new Gilead CEO Daniel O’Day.

A long-term perspective

Gilead Sciences and Galapagos are working together on the experimental JAK1 inhibitor filgotinib for rheumatoid arthritis. Gilead has agreed to pay $3.95 billion upfront to Galapagos. It will take a $1.1 billion equity investment in the company and increase its stake to 22%. Another $1.1 billion are dedicated to opt-in payments for two late-stage drugs.

Gilead Set to Acquire Higher Stake in Galapagos for $5.1 Billion

The 10-year research & development alliance is crucial for Gilead as it could introduce six new compounds to the firm’s clinic programs and another 20 in preclinical programs. The biotech firm is already suffering because of staggering declines in its hepatitis C sales. Its HIV franchise is also under pressure and one of its biggest stakes, cancer and live diseases, are still being worked upon.

Gilead needs to rebuild its pipeline

The company acquired Kite for $12 billion to get hold of CAR-T therapy for cancer Yescarta (axicabtagene ciloleucel). However, the sales for the product are dismal and brought only $264 million in 2018. It’s lead non-alcoholic steatohepatitis (NASH) therapy selonsertib also experienced two failed trials.

O’Day, who took over as CEO this March, sees the reinvigoration of the company’s pipeline as his top priority. As revenues are already disappointing, it will be worthwhile to give the company a new direction. With the new deal with Galapagos, the company will add the oral, once-daily autotaxin inhibitor for idiopathic pulmonary fibrosis (IPF) in phase 3. Another interesting addition will be GLPG1972, an ADAMTS-5 blocker for osteoarthritis in phase 2B. The drug is targeted at the US market as Servier holds its rights for international markets.

The company’s new deal also brings option rights to all current and future clinical programs of Galapagos outside Europe. O’Day commented on the partnership, complimenting the Belgian biotech for its pioneering target and drug discovery platform, great team and proven scientific abilities.

For Galapagos, this high-stakes acquisition brings a truckload of financial prowess, especially as it tries to become one of the top 10 biotech firms as well as a commercial-stage company. It also seeks commercialization rights for filgotinib in Europe, so the drug could be launched in 2020. Gilead also brings more experience and commercial acumen to the Belgian firm and help it double down on R&D without losing its independence.

All trading carries risk. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.

Viraj Shah

Viraj loves to write and express his views on anything related to Finance, Crypto, or Fintech. He has been covering Finance & Crypto for more than five years now. He likes Tesla. He also writes on Healthcare, and Technology among other stuff.
HTML Snippets Powered By : XYZScripts.com